The Very Good News
Labor lawyer and phenominee Nicole Berner [[link removed]] was confirmed to the Fourth Circuit this week by a vote of 50 to 47. With legal experience spanning from labor law to reproductive rights, Berner is an outstanding addition to the federal judiciary β and her confirmation brings the total number of out LGBTQ+ judges confirmed under Biden to 11, the same as President Barack Obama confirmed over two terms. Judge Berner is only the third openly LGBTQ+ woman [[link removed]] to serve as a federal appellate judge.
Meanwhile, Judge Eumi Lee, another AFJ priority nominee, was confirmed slightly more narrowly β 50 to 49βto the U.S. District Court for the Northern District of California on Wednesday afternoon. Until her confirmation to the federal bench, Judge Lee sat on the Superior Court of California in Alameda County. Previously, Lee taught at the University of California College of Law in San Francisco. There, she directed the Individual Representation Clinic, which represented indigent and low-income individuals.
[[link removed]]
More Good Things from the Hill
On Wednesday, the SJC held a nomination hearing for nominees Sparkle Sooknanan (D.D.C), a former Sotomayor clerk and Jones Day alumna; Angela M. Martinez (D. Ariz.); Krissa M. Lanham (D. Ariz.); Georgia Alexakis (N.D. Ill.); and, first among equals, Nancy L. Maldonado [[link removed]] , currently on the Northern District Court for the District of Illinois, who is up for confirmation to the Seventh Circuit.
Judge Maldonado is one of our priority nominees. She is a movement lawyer through-and-through with decades of experience in labor and employment law. AFJ first had the privilege of supporting Maldonadoβs nomination to the federal bench in 2022 and we are thrilled to see a jurist of her caliber elevated to the appellate bench. Upon confirmation, Maldonado will be the first Latino judge to serve on the Seventh Circuit β just as she was on the district court.
[link removed] [[link removed]]
Whatβs Next: Reproductive Rights Under Fire
On Tuesday, March 26, the Supreme Court will hear oral arguments in U.S. Food and Drug Administration v. Alliance for Hippocratic Medicine [[link removed]] .
Need a primer? Weβve got you covered: This landmark case concerns access to mifepristone, a medication used in more than half of abortions [[link removed]] in the United States. The FDA first approved mifepristone for use in abortions in 2000. In the 24 years since, the FDA expanded access to the medication, proved safe over and over again, which is also used for miscarriage treatment.
Originally, patients could only obtain the medication after three in-person visits to a doctor [[link removed]] . After reviewing substantial evidence of the drugβs safety and efficacy, the FDA overturned the three-visit requirement and allowed mifepristone to be prescribed via telehealth [[link removed]] . Last year, the Alliance for Hippocratic Medicine, a litigious anti-choice group, tried to backdate its objections to the medication, suing the FDA over its initial approval of the medication as well as recent regulations expanding access.
A Reminder of Structural Obstacles
Anti-choice activists, among others, have been forum-shopping β and judge-shopping for years, seeking out the most sympathetic β and least principled β jurists they could find to bring their oft-shaky claims. In the mifepristone case, they filed their suit against the FDA before Judge Mathew Kacsmaryk in the U.S. District Court for the Northern District of Texas
More context? In 2023, the infamously anti-choice [[link removed]] Judge Kacsmaryk ruled that the FDA erred by approving mifepristone [[link removed]] in 2000 and issued a nationwide injunction [[link removed]] on the medication. That same day, a Washington state district court judge [[link removed]] ruled the opposite way, prompting the Supreme Court to issue a stay [[link removed]] of Kacsmarykβs ruling pending further litigation.
On appeal, the Fifth Circuit limited Kacsmarykβs holding, [[link removed]] overturning the new regulations expanding access but letting the drugβs original approval stand. The March 26 arguments mark the next stage in this saga and the first time [[link removed]] that the Supreme Court has ruled on a major abortion access issue since overturning Roe v. Wade . The Courtβs opinion in the so-called βmifeβ case will have huge implications for patientsβ access to safe and effective reproductive health care nationwide.
Not yet receiving AFJ Insider? Sign up to join us here [[link removed]] .
Donate today to help us keep up The Rush. [[link removed]]
[[link removed]]
[link removed] [[link removed]] [link removed] [[link removed]] [link removed] [[link removed]] [link removed] [[link removed]] [link removed] [[link removed]] www.afj.org [www.afj.org]
If you believe you received this message in error or wish to no longer receive email from us, please unsubscribe: [link removed] .
Alliance for Justice
11 Dupont Circle NW
Suite 500
Washington, DC 20036
United States